Generics

Filter

Current filters:

None

Popular Filters

27 to 51 of 1234 results

Australia’s TGA joins EDQM's CEP assessment process

Australia’s TGA joins EDQM's CEP assessment process

17-06-2014

The Australian Therapeutic Goods Administration (TGA) is set to strengthen its collaboration with the…

AustraliaEuropeGenericsRegulation

US Court denies appeal in Baraclude patent case

US Court denies appeal in Baraclude patent case

13-06-2014

US pharma major Bristol-Myers Squibb yesterday announced that the US Court of Appeals for the Federal…

Anti-viralsBaracludeBristol-Myers SquibbGenericsLegalPatentsTeva Pharmaceutical IndustriesUSA

Meiji Seika Pharma to acquire India’s Medreich for $290 million

Meiji Seika Pharma to acquire India’s Medreich for $290 million

12-06-2014

Japan’s Meiji Seika Pharma revealed today that it intends to acquire all of the outstanding shares…

Asia-PacificGenericsMedreichMeiji Seika PharmaMergers & Acquisitions

Mylan launches generic Paraplatin Injection in USA

Mylan launches generic Paraplatin Injection in USA

09-06-2014

US generics major Mylan has launched carboplatin injection, 50mg/5ml, in multi-dose vials, which is the…

Bristol-Myers SquibbGenericsMarkets & MarketingMylanOncologyParaplatinRegulationUSA

Report highlights approvals, challenges and deals in the generics sector

Report highlights approvals, challenges and deals in the generics sector

09-06-2014

India-based groups received the most approvals for Abbreviated New Drug Applications from the US Food…

GenericsMarkets & MarketingUSA

Hospira refutes high pricing of paclitaxel during drug shortage

Hospira refutes high pricing of paclitaxel during drug shortage

08-06-2014

The Canadian subsidiary of USA-based injectable generic drugs specialist Hospira has refuted press reports…

CanadaGenericsHospiraMarkets & MarketingOncologyPaclitaxelPricing

Lupin no longer trying to market generics of Truvada and Viread

Lupin no longer trying to market generics of Truvada and Viread

08-06-2014

Indian drugmaker Lupin seems to have abandoned plans to bring to market generic versions of Gilead Sciences’…

Anti-viralsGenericsGilead SciencesLegalLupinPatentsTruvadaUSAViread

Fight the Fakes campaign gains momentum as 11 new partners join global movement

Fight the Fakes campaign gains momentum as 11 new partners join global movement

06-06-2014

Following the campaign’s six-month anniversary, Fight the Fakes has announced 11 new partners, bringing…

GenericsGlobalMarkets & Marketing

Ranbaxy’s Toansa plant assessment concluded: no risk to public health, EU view

Ranbaxy’s Toansa plant assessment concluded: no risk to public health, EU view

05-06-2014

European regulatory authorities have finalized their assessment of reported non-compliance with Good…

EuropeGenericsIndiaProductionRanbaxy LaboratoriesRegulation

Generic and biosimilar drugs should be key components of CSRs for health, says EGA

Generic and biosimilar drugs should be key components of CSRs for health, says EGA

05-06-2014

The increased number of health related proposed country specific recommendations (CSR) to European Union…

BiosimilarsGenericsHealthcareRegulation

European generics group welcomes WHA resolution on biotherapeutics products

04-06-2014

The European Generic Medicines Association (EGA) has welcomed the 67th World Health Assembly’s Resolution…

BiosimilarsGenericsGlobalRegulation

EGA calls for international regulatory cooperation

03-06-2014

European Generics Medicines Association (EGA) Director General Adrian van den Hoven last week joined…

GenericsGlobalPharmaceutical industryRegulationResearch

AMRI to buy Oso Biopharmaceuticals Manufacturing for $110 million

AMRI to buy Oso Biopharmaceuticals Manufacturing for $110 million

02-06-2014

USA-based Albany Molecular Research has signed a definitive agreement to acquire all of the outstanding…

Albany Molecular ResearchGenericsMergers & AcquisitionsOso BiopharmaceuticalsProduction

Actavis brings escitalopram to market after patent expiry

Actavis brings escitalopram to market after patent expiry

02-06-2014

Generics major Actavis (NYSE: ACT) has launched escitalopram tablets in the UK today, following the patent…

ActavisCNS DiseasesEscitalopramEscitalopram OxalateGenericsLexaproLundbeckPatentsUK

Actavis settles Nuvigil patent litigation with Cephalon

Actavis settles Nuvigil patent litigation with Cephalon

01-06-2014

Ireland-headquartered generics major Actavis says it has entered into an agreement with Cephalon to settle…

ActavisCephalonGenericsLegalNeurologicalNuvigilPatentsTeva Pharmaceutical IndustriesUSA

European and Japanese generics groups view opportunities on biosimilars

European and Japanese generics groups view opportunities on biosimilars

29-05-2014

The European Generic Medicines Association (EGA) participated in several meetings with Japanese government…

BiosimilarsEuropeGenericsJapanMarkets & MarketingRegulation

Hikma to buy Boehringer’s Bedford Labs unit for $300 million

Hikma to buy Boehringer’s Bedford Labs unit for $300 million

28-05-2014

Jordon-based drugmaker Hikma Pharmaceuticals has signed an asset purchase agreement with Ben Venue Laboratories,…

Bedford LaboratoriesBoehringer IngelheimGenericsHikma PharmaceuticalsMergers & AcquisitionsUSA

Actavis challenges AstraZeneca’s diabetes drug Onglyza patent in the USA

Actavis challenges AstraZeneca’s diabetes drug Onglyza patent in the USA

28-05-2014

Generics major Actavis yesterday confirmed that it has filed an Abbreviated New Drug Application with…

ActavisAstraZenecaDiabetesGenericsOnglyzaPatentsUSA

Recordati finalizes second tranche of Opalia Pharma acquisition

27-05-2014

Following previous announcements about its M&A activity, Italian drugmaker Recordati has now announced…

GenericsMergers & AcquisitionsOpalia PharmaRecordatiRest of the World

Congressional hearing in Brazil will discuss the efficacy of generic medicines

26-05-2014

The Brazilian Commission for Consumer Protection will soon hold a hearing to discuss the effectiveness…

BrazilGenericsPoliticsRegulation

Indian court ruling lifts temporary stay on Sun Pharma takeover of Ranbaxy

26-05-2014

Indian generics drugmaker Sun Pharmaceuticals’ proposed $3.2 billion acquisition of loss-making rival…

Daiichi SankyoGenericsLegalMergers & AcquisitionsRanbaxy LaboratoriesSun Pharmaceuticals

27 to 51 of 1234 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top